

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**LUYE PHARMA GROUP LTD.**

**绿叶制药集团有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 02186)**

**VOLUNTARY ANNOUNCEMENT**

**INNOVATIVE FORMULATIONS BAITUOWEI AND RYKINDO INCLUDED ON  
CHINA'S 2023 NATIONAL REIMBURSEMENT DRUG LIST**

The board of directors (the “**Board**”) of Luye Pharma Group Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that two of the Group’s in-house developed innovative formulations have been included on the National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2023 Version) (the “**2023 National Reimbursement Drug List**”). The two formulations are Baituowei (Goserelin Microspheres for Injection) and Rykindo (Risperidone Microspheres for Injection (II)). Baituowei is being included in the list for the first time. Rykindo is included in the list again under a renewed contract, maintaining the same payment standard under the health insurance remaining. The 2023 National Reimbursement Drug List will become effective on 1 January 2024.

**BAITUOWEI**

Baituowei was approved for marketing in China in June 2023 for the treatment of prostate cancer in patients who need androgen deprivation therapy. This indication is now covered by the 2023 National Reimbursement Drug List. In addition, Baituowei was also approved in China in September 2023 for the treatment of breast cancer in premenopausal and perimenopausal women who can be treated with hormones.

Developed on the Group’s microsphere platform, Baituowei is currently the only long-acting microsphere formulation of goserelin approved for use, as far as the Company is aware. With its upgraded microsphere formulation and improved injection style, Baituowei is able to maintain a

balance of efficacy, safety, and patient experience, and offers a more convenient option for patients. The Group and BeiGene, Ltd. (a company listed on The Stock Exchange of Hong Kong Limited (stock code: 06160)) are working together to commercialize this product in China.

## **RYKINDO**

Rykindo was approved for launch in China in January 2021 for the treatment of patients with acute and chronic schizophrenia and other psychotic conditions with clear positive or negative symptoms. The contract for this product with the health insurance authority in China has been successfully renewed, securing its place on the 2023 National Reimbursement Drug List with the payment standard remaining unchanged.

Rykindo combines the benefits of a long-acting injection and an atypical antipsychotic. With its unique pharmacokinetic profile and pharmacodynamic property, Rykindo has been proven to be effective and safe throughout the treatment process for schizophrenia patients.

In addition to China, Rykindo was also approved for marketing by the U.S. Food and Drug Administration (“**FDA**”) in January 2023. As far as the Company is aware, this product is the first new drug in the central nervous system therapeutic area developed by a Chinese pharmaceutical company approved for launch in the U.S., and the first FDA-approved complex dosage form product developed by a pharmaceutical company in Mainland China in accordance with section 505(b)(2) of the Federal Food, Drug and Cosmetic Act.

The Company believes that including innovative products such as Baituwei and Rykindo in the National Reimbursement Drug List of China’s health insurance system make them accessible to patients at lower prices under insurance, thereby reducing the financial burdens of patients. This also helps to accelerate the commercialization of these products and further increase the rewards for innovation.

By Order of the Board  
**LUYE PHARMA GROUP LTD.**  
**Liu Dian Bo**  
*Chairman*

Hong Kong, 13 December 2023

*As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Dr. LYU Dong; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.*